Profile
20/20 OptimEyes Technologies has developed a mucoadhesive drug delivery platform technology that allows for improved solubility of APIs and extended release. Validated as an eye drop, 20/20 OptimEyes has a successful lead pre-clinical program in glaucoma for which the company is seeking investment. It is also interested in partners with novel or repurposed APIs targeting mucosal areas for co-development opportunities.
Website
Contact
-
Frances Lasowski, Chief Executive OfficerTel: +1 905-978-9262Email: frances@2020optimeyes.ca
-
-
-
-
-
Event details
Date: September 25 - 27, 2024
Event contact
Patricia Cosgrove
Area Director
USA: Life Sciences
Tel: +1 647-293-6306
Email: patricia.cosgrove@ontario.ca
Participants
13 in total
-
20/20 OptimEyes Technologies has developed a mucoadhesive drug delivery platform technology that allows for…
-
CanaQuest is a clinical-stage life sciences company developing innovative cannabinoid-based therapeutics. Its… -
Canurta stands at the forefront of biotechnological innovation, developing new small-molecule therapeutics from… -
Healthyher.Life is a women’s health navigator platform for its member community of women and gender-diverse… -
Hole Medical Ltd. is a pioneering digital health aggregator at the forefront of healthcare innovation. Its… -
ImmunoBiochem is an innovative biopharmaceutical company on a mission to develop novel bioconjugate therapeutics… -
For over two decades, Inertia has been the trusted partner for start-ups in the medical device, diagnostic, and… -
JN Nova Pharma is a Canadian biotech company collaborating with the National Research Council of… -
Noa Therapeutics is a preclinical biotech company pioneering the development of homeostatic modulating small… -
ProteinQure has built the best computational platform for designing peptides for extra-cellular targets. Its lead… -
PurMinds is a neuro-medicine company pursuing breakthrough solutions to neurological disorders by leveraging… -
QurCan Therapeutics is a biotechnology company that has developed the next-generation nanoparticle for safer and… -
VeriLuce Therapeutics is an R&D/early-stage drug development company currently developing novel small…